Dose dependence of chronic positive inotropic effect of vesnarinone in patients with congestive heart failure due to idiopathic or ischemic cardiomyopathy

American Journal of Cardiology

Volumn 78, Issue 6, 1996, Pages 652-656

  Kass, David A ^a   Van Anden, Elizabeth ^b   Becker, Lewis C ^b   Kasper, Edward K ^b   White, William B ^b   Feldman, Arthur M ^b  

^a JOHNS HOPKINS HOSPITAL   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CARDIOTONIC AGENT; PIPERANOMETOZINE; QUINOLINE DERIVATIVE;

ARTICLE; CARDIOMYOPATHY; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; HEART VENTRICLE FUNCTION; HEMODYNAMICS; HUMAN; ORAL DRUG ADMINISTRATION; PATHOPHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; REGRESSION ANALYSIS;

ADMINISTRATION, ORAL; CARDIOMYOPATHIES; CARDIOTONIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; HEART FAILURE, CONGESTIVE; HEMODYNAMIC PROCESSES; HUMANS; QUINOLINES; REGRESSION ANALYSIS; VENTRICULAR FUNCTION;

EID: 0030587270     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(96)00388-8     Document Type: Article

References (28)

1. Feldman AM, Bristow MR, Parmley WW, Carson PE, Pepine CJ, Gilbert EM, Strobeck JE, Hendrix GH, Powers ER, Bain RP, White BG, for the Vesnarinone Study Group. Effects of vesnarinone on morbidity and mortality in patients with heart failure. N Engl J Med 1993;329:149-155.
2. Feldman AM, Becker LC, Llewellyn MP, Baughman KL. Evaluation of a new inotropic agent, OPC-8212, in patients with dilated cardiomyopamy and heart failure. Am Heart J 1988;116:771-776.
3. OPC-8212 Multicenter Research Group. A placebo-controlled, randomized, double-blind study of OPC-8212 in patients with mild chronic heart failure. Cardiovasc Drugs Ther 1990;4:419-425.
4. Inoue M, Kim BH, Hori M, Tsuneoka Y, Matsubara N, Kamada T, Kodama KI, Naka M, Nanto S, Higashino Y. Oral OPC-8212 for the treatment of congestive heart failure: hemodynamic improvement and increased exercise capacity. Heart Vessels 1986;2:166-171.
5. Iijima T, Taira N. Membrane current changes responsible for the positive inotropic effect of OPC-8212, a new positive inotropic agent, in single ventricular cells of the guinea pig heart. J Pharmacol Exp Ther 1987;240:657-662.
6. Rapundalo ST, Lathrop DA, Harrison SA, Beavo JA, Schwartz A. Cyclic AMP-dependent and cyclic-AMP-independent actions of novel cardiotonic agent, OPC-8212, Naunyn-Schmiedebergs Arch Pharmacol 1988;338:692-698.
7. Lathrop DA, Nanasi PP, Schwartz A, Varro A. Ionic basis for OPC-8212-induced increase in action potential duration in isolated rabbit, guinea pig, and human ventricular myocytes. Eur J Pharmacol 1993;240:127-137.
8. Yanagisawa T, Endoh M, Taira N. Involvement of cyclic AMP in the positive inotropic effect of OPC-8212, a new cardiotonic agent, on the canine ventricular muscle. Jpn J Pharmacol 1984;36:379-388.
9. 2+ channels in ventricular myocytes of guinea pig. J Cardiovasc Pharmacol 1989;13:812-819.
10. Endoh M, Yanagisawa T, Taira N, Blinks JR. Effects of new inotropic agents on cyclic nucleotide metabolism and calcium transients in canine ventricular muscle. Circulation 1986;73(suppl III):III-117-III-133.
11. Miyazaki S, Sasayama S, Nakamura Y, Kihara Y, Susawa T, Kawai C. Acute hemodynamic effects of a new positive inotropic agent, 3,4-dihydro-6-[4-(3,4-dimethoxybenzoyl)-1-piperazinyl]-2(1H)-quinolinone (OPC-8212), in conscious and anesthetized dogs. J Cardiovasc Pharmacol 1986;8:14-20.
12. 2+ antagonist pretreatment. Jpn Circ J 1986;50:37-44.
13. Nishiyama Y, Takeda K, Nakamura Y, Masuda T, Yagi S. Effect of vesnarinone on the myocardial force-length relationship in the in situ canine left ventricle. J Cardiol 1994;24:149-154.
14. Kubo SH, Rector TS, Strobeck JE, Cohn JN. OPC-8212 in the treatment of congestive heart failure. Results of a pilot study. Cardiovasc Drugs Ther 1988;2:653-660.
15. Asanoi H, Sasayama S, Kameyama T, Ishizaka S, Iuchi K. Sustained inotropic effects of a new cardiotonic agent. OPC-8212 in patients with chronic heart failure. Clin Cardiol 1989;12:133-138.
16. Ohnishi A, Ishizaki T. Pharmacokinetic profile of OPC-8212 in humans: a new, nonglycosidic inotropic agent. J Clin Phamacol 1988;28:719-726.
17. Sharir T, Feldman MD, Haber H, Feldman AM, Marmor A, Becker LC, Kass DA. Ventricular systolic assessment in patients with dilated cardiomyopathy by preload-adjusted maximal power: validation and noninvasive application. Circulation 1994;89:2045-2053.
18. Sharir T, Marmor A, Ting CT, Chen JW, Liu CP, Chang MS, Yin FCP, Kass DA. Validation of a method for noninvasive measurement of central arterial pressure. Hypertension 1993;21:74-82.
19. Marmor A, Sharir T, Ben Shlomo I, Beyar R, Frenkel A, Front D. Radio-nuclide ventriculography and central aorta pressure change in noninvasive assessment of myocardial performance. J Nucl Med 1989;30:1657-1665.
20. Kass DA, Beyar R. Evaluation of contractile state by maximal ventricular power divided by the square of end-diastolic volume. Circulation 1991; 84:1698-1708.
21. Links JM, Becker LC, Shindledecker JG, Guzman P, Burow RD, Nickoloff EL, Alderson PO, Wagner HN. Measurement of absolute left ventricular volume from gated blood pool studies. Circulation 1982;65:82-91.
22. Sunagawa K, Maughan WL, Burkhoff D, Sagawa K. Left ventricular interaction with arterial load studied in isolated canine ventricle. Am J Physiol 1983;245:H773-H780.
23. Kelly RP, Ting CT, Yang TM, Maughan WL, Chang MS, Kass DA. Effective arterial elastance as index of arterial vascular load in humans. Circulation 1992;86:513-521.
24. Feldman MD, Copelas L, Gwathmey JK, Phillips P, Warrent SE, Schoen FJ, Grossman W, Morgan JP. Deficient production of cyclic AMP: Pharmacologic evidence of an important cause of contractile dysfunction in patients with end-stage heart failure. Circulation 1987;75:331-339.
25. Packer M, Carver JR, Rodeheffer RJ, Ivanhoe RJ, DiBianco R, Zeldis SM, Hendrix GH, Bommer WJ, Elkayam U, Kukin ML, Mallis GI, Sollano JA, Shannon J, Tandon PK, deMets DL. Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. N Engl J Med 1991;325:1468-1475.
26. Feldman AM. Can we alter survival in patients with congestive heart failure? JAMA 1992;267:1956-1960.
27. Matsumori A, Shioi T, Yamada T, Matsui S, Sasayama S. Vesnarinone, a new inotropic agent, inhibits cytokine production by stimulated human blood from patients with heart failure. Circulation 1994;89:955-998.
28. Matsui S, Matsumori A, Matoba Y, Uchida A, Sasayama S. Treatment of virus-induced myocardial injury with a novel immunomodulating agent, vesnarinone. Suppression of natural killer cell activity and tumor necrosis factor-alpha production. J Clin Invest 1994;94:1212-1217.